Related Experiment Videos
Antiapoptosis potential of bcl-2 oncogene by dephosphorylation
1Jefferson Cancer Institute, Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Abstract:
The antiapoptosis potential of bcl-2 has now been well established. But the biochemical mechanism of bcl-2 action is still poorly understood. Using the phosphatase inhibitor okadaic acid (OA) or chemotherapeutic agents such as Taxol and 5'-fluorouracil, we found that bcl-2 can be phosphorylated. Since OA or Taxol treatment leads to apoptosis, it seems that phosphorylation of bcl-2 leads to its inactivation. Exposure of several lymphoid cell lines expressing differential amounts of bcl-2 protein to OA resulted in apoptosis of the cells and hyperphosphorylation of bcl-2. Interestingly, the lymphoblastoid cell lines that did not phosphorylate bcl-2 following OA exposure did not undergo apoptosis. Moreover, pro-B cells isolated from patients with acute lymphoblastic leukemias exhibited endogenous phosphorylated forms of bcl-2 and a large number of apoptotic cells, even without OA treatment. Treatment with the phosphatase inhibitor or with chemotherapeutic agents (Taxol, 5'-fluorouracil) led to severe apoptosis of these cells, along with hyperphosphorylation of bcl-2. Phosphoamino acid analysis reveals that bcl-2 is phosphorylated at a serine residue. In summary, our investigation indicates that the phosphorylation pathway involving bcl-2 can be the determinant of cell death in lymphocytes.
Insights
Phosphorylation inactivates the anti-apoptotic protein bcl-2, promoting lymphocyte cell death. This finding reveals a key mechanism in apoptosis regulation and potential therapeutic targets for lymphoid malignancies.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- The anti-apoptotic function of B-cell lymphoma 2 (bcl-2) is established, but its precise biochemical mechanism remains unclear.
- Understanding bcl-2's regulation is crucial for controlling lymphocyte cell death and treating related diseases.
Purpose of the Study:
- To investigate the role of bcl-2 phosphorylation in lymphocyte apoptosis.
- To elucidate the biochemical pathway linking bcl-2 activity to cell death.
Main Methods:
- Treatment of lymphoid cell lines with phosphatase inhibitors (okadaic acid) and chemotherapeutic agents (Taxol, 5'-fluorouracil).
- Analysis of bcl-2 phosphorylation status and correlation with apoptosis induction.
- Phosphoamino acid analysis to identify phosphorylation sites.
Main Results:
- Okadaic acid and chemotherapeutic agents induced bcl-2 phosphorylation, correlating with apoptosis.
- Lymphoid cells that did not phosphorylate bcl-2 upon treatment did not undergo apoptosis.
- Endogenous phosphorylated bcl-2 and apoptosis were observed in pro-B cells from acute lymphoblastic leukemia patients.
- Phosphorylation occurs at a serine residue on bcl-2.
Conclusions:
- Bcl-2 phosphorylation appears to inactivate its anti-apoptotic function, promoting lymphocyte cell death.
- The phosphorylation status of bcl-2 is a critical determinant of lymphocyte survival or apoptosis.
- These findings suggest that targeting the bcl-2 phosphorylation pathway could be a therapeutic strategy for lymphoid cancers.